@article{CCO20028,
author = {Minya Yao and Peifen Fu},
title = {Advances in anti-HER2 therapy in metastatic breast cancer},
journal = {Chinese Clinical Oncology},
volume = {7},
number = {3},
year = {2018},
keywords = {},
abstract = {Though most patients with breast cancer are cured, there are still many patients progressed to metastatic breast cancer (MBC) and some are diagnosed as MBC. Human epidermal growth factor receptor 2 (HER2) is positive in about 20% all breast cancer patients and considered as a poor prognostic factor. The advent of ant-HER2 therapy has prominently prolonged the time of disease progression and survival for HER2-positive MBC patients. This review summarizes the advance in anti-HER2 therapy in HER2-positive MBC according to the phase III clinical trials, and briefly discusses some new agents and anti-HER2 therapy for HER2 low-or non-expression breast cancer patients.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/20028}
}